Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost
Envelopes of primary R5-tropic human immunodeficiency virus type 1 (HIV-1) isolates may be particularly relevant for vaccine purposes and should be evaluated for immunogenicity in animals including macaques before carrying out human vaccine trials. In the present study, the immunogenicities of synthetic HIV-1 env DNA vaccines, which had been derived from the early primary isolate Bx08 and contain humanized codons, were evaluated in mice, guinea pigs and rhesus macaques. Neutralization sensitivity of the HIV-1Bx08 isolate was found to resemble that of other primary isolate prototypes. Immunogenicity of gp120 delivered as codon-optimized DNA vaccine was comparable to that of recombinant gp120 protein plus adjuvant in mice. Similarly, DNA vaccination of guinea pigs with synthetic gp140Bx08 and gp150Bx08 DNA induced a strong antibody response independent of the gene construct and DNA immunization route. Mamu-A*01 rhesus macaques were DNA vaccinated with synthetic gp150Bx08 or gp140Bx08 DNA and boosted with a replication-deficient recombinant human adenovirus type 5 expressing a synthetic gp120Bx08 gene. DNA-vaccinated rhesus macaques developed specific CD8+ T lymphocyte responses and anti-rgp120IIIb antibody responses. Both the humoral and cellular responses were significantly improved following intramuscular boosting with the recombinant adenovirus. The demonstrated humoral and cellular immunogenicities of these HIV Bx08 Env vaccines in non-human primates encourages their further development as one component in candidate HIV vaccines for humans.
AllenT. M.,
VogelT. U.,
FullerD. H.11 other authors2000; Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164:4968–4978
AndréS.,
SeedB.,
EberleJ.,
SchrautW.,
BültmannA.,
HaasJ.1998; Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72:1497–1503
BarnettS.,
KlingerJ. M.,
DoeB.,
WalkerC. M.,
HansenL.,
DuliégeA.,
SinangilF. M.1998; Prime-boost immunization strategies against HIV. AIDS Res Hum Retroviruses 14:s299–310
BarouchD. H.,
SantraS.,
SchmitzJ. E.23 other authors2000; Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290:486–492
BeddowsS.,
LouisirirotchanakulS.,
Cheingsong-PopovR.,
EasterbrookP. J.,
SimmondsP.,
WeberJ.1998; Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol 79:77–82
BerliozT. C.,
ShacklettB. L.,
ErdtmannL.,
DelamarreL.,
BouchaertI.,
SonigoP.,
DokhelarM. C.,
BenarousR.1999; Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrinadaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 73:1350–1361
BruceC. B.,
AkriggA.,
SharpeS. A.,
HankeT.,
WilkinsonG. W.,
CranageM. P.1999; Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol 80:2621–2628
BugeS. L.,
MurtyL.,
AroraK.8 other authors1999; Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 73:7430–7440
BuresR.,
GaitanA.,
ZhuT.13 other authors2000; Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 16:2019–2035
BuresR.,
MorrisL.,
WilliamsonC.,
RamjeeG.,
DeersM.,
FiscusS. A.,
Abdool-KarimS.,
MontefioriD. C.2002; Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 76:2233–2244
BurtonD. R.,
PyatiJ.,
KoduriR.7 other authors1994; Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024–1027
ConleyA. J.,
KesslerJ. A.II,
BootsL. J.9 other authors1996; The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 70:6751–6758
ConnorR. I.,
KorberB. T. M.,
GrahamB. S. & 17 authors; 1998; Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol 72:1552–1576
CorbetS.,
VinnerL.,
HougaardD. M.,
BryderK.,
NielsenH. V.,
NielsenC.,
FomsgaardA.2000; Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 16:1997–2008
EganM. A.,
KurodaM. J.,
VossG.,
SchmitzJ. E.,
ChariniW. A.,
LordC. I.,
FormanM. A.,
LetvinN. L.1999; Use of major histocompatibility complex class I/peptide/β2M tetramers to quantitate CD8+ cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys. J Virol 73:5466–5472
FollisK. E.,
TraheyM.,
LaCasseR. A.,
NunbergJ. H.1998; Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1. J Virol 72:7603–7608
FrancisD. P.,
GregoryT.,
McElrathM. J.8 other authors1998; Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 14:S325–332
GartnerS.,
MarkovitsP.,
MarkovitzD. M.,
KaplanM. H.,
GalloR. C.,
PopovicM.1986; The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215–219
GrahamB. S.,
McElrathM. J.,
ConnorR. I.16 other authors1998; Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis 177:310–319
HankeT.,
SamuelR. V.,
BlanchardT. J.9 other authors1999; Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73:7524–7532
KamstrupS.,
San MartinR.,
DobertiA.,
GrandeH.,
DalsgaardK.2000; Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A. Vaccine 18:2244–2249
KentS. J.,
ZhaoA.,
BestS. J.,
ChandlerJ. D.,
BoyleD. B.,
RamshawI. A.1998; Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72:10180–10188
LaBrancheC. C.,
SauterM. M.,
HaggartyB. S.,
VanceP. J.,
RomanoJ.,
HartT. K.,
BugelskiP. J.,
MarshM.,
HoxieJ. A.1995; A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol 69:5217–5227
LuS.,
WyattR.,
RichmondJ. F.,
MustafaF.,
WangS.,
WengJ.,
MontefioriD. C.,
SodroskiJ.,
RobinsonH. L.1998; Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14:151–155
MascolaJ. R.,
SnyderS. W.,
WeislowO. S.17 other authors1996; Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173:340–348
MascolaJ. R.,
StieglerG.,
VanCottT. C.& 11 other authors2000; Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207–210
McCluskieM. J.,
MillanC. L. B.,
GramzinskiR. A.7 other authors1999; Route and method of delivery of DNA vaccine influences immune responses in mice and non-human primates. Mol Med 5:287–300
MontefioriD. C.,
SafritJ. T.,
LydyS. L.7 other authors2001; Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 75:5879–5890
MoogC.,
SpenlehauerC.,
FleuryH. J.,
HeshmatiF.,
SaragostiS.,
LetourneurF.,
KirnA.,
AubertinA. M.1997b; Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses 13:19–27
MooreJ. P.,
BurklyL. C.,
ConnorR. I.,
CaoY.,
TizardR.,
HoD. D.,
FisherR. A.1993; Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res Hum Retroviruses 9:529–539
MooreJ. P.,
CaoY.,
QingL.,
SattentauQ. J.7 other authors1995; Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69:101–109
MusterT.,
SteindlF.,
PurtscherM.,
TrkolaA.,
KlimaA.,
HimmlerG.,
RükerF.,
KatingerH.1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67:6642–6647
NatukR. J.,
ChandaP. K.,
LubeckM. D.7 other authors1992; Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci U S A 89:7777–7781
NielsenC. M.,
BygbjergI. C.,
VestergaardB. F.1987; Detection of HIV antigens in eluates from whole blood collected on filterpaper [letter]. Lancet i:566–567
NyambiP. N.,
NadasA.,
MbahH. A.,
BurdaS.,
WilliamsC.,
GornyM. K.,
Zolla-PaznerS.2000; Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol 74:10670–10680
ParrenP. W.,
GauduinM. C.,
KoupR. A.,
PoignardP.,
FisicaroP.,
BurtonD. R.,
SattentauQ. J.1997; Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 57:105–112
RichmondJ. F.,
LuS.,
SantoroJ. C.,
WengJ.,
HuS. L.,
MontefioriD. C.,
RobinsonH. L.1998; Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 72:9092–9100
RobinsonH. L.,
MontefioriD. C.,
JohnsonR. P.14 other authors1999; Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5:526–534
SorensenN. S.2001; On the effect of antibodies on the humoral response to protein antigens
. PhD thesis Faculty of Health Sciences, University of Copenhagen; Denmark:
StamatatosL.,
Cheng-MayerC.1998; An envelope modification that renders a primary, neutralisation resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 72:7840–7845
TrkolaA.,
PurtscherM.,
MusterT.7 other authors1996; Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100–1108
WeeE. G. T.,
PatelS.,
McMichaelA. J.,
HankeT.2002; A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83:75–80
WrinT.,
LohT. P.,
VennariJ. C.,
SchuitemakerH.,
NunbergJ. H.1995; Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 69:39–48
ZhangY. J.,
FredrikssonR.,
McKeatingJ. A.,
FenyoE. M.1997; Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. Virology 238:254–264
ZhouJ. Y.,
MontefioriD. C.1997; Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells. J Virol 71:2512–2517
Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost